Abstract
The pandemic caused by SARS-CoV-2 has proven challenging clinically, and at the population level, due to heterogeneity in both transmissibility and severity. Recent case incidence in Ontario, Canada (autumn 2020) has outstripped incidence in seen during the first (spring) pandemic wave; but has been associated with a lower incidence of intensive care unit (ICU) admissions and deaths. We hypothesized that differential ICU burden might be explained by increased testing volumes, as well as the shift in mean case age from older to younger. We constructed a negative binomial regression model using only three covariates, at a 2-week lag: log10(weekly cases); log10(weekly deaths); and mean weekly case age. This model reproduced observed ICU admission volumes, and demonstrated good preliminary predictive validity. Furthermore, when admissions were used in combination with ICU length of stay, our modeled estimates demonstrated excellent convergent validity with ICU occupancy data reported by the Canadian Institute for Health Information. Our approach needs external validation in other settings and at larger and smaller geographic scales, but appears to be a useful short-term forecasting tool for ICU resource demand; we also demonstrate that the virulence of SARS-CoV-2 infection has not meaningfully changed in Ontario between the first and second waves, but the demographics of those infected, and the fraction of cases identified, have.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was supported by a grant to DNF from the Canadians Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by the Research Ethics Board of the University of Toronto
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The research was supported by a grant to DNF from the Canadians Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360).
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.